BioPorto A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THOXF research report →
Price Chart
About the company
BioPorto A/S is an in-vitro diagnostics firm that supplies diagnostic tools and antibodies globally to medical professionals and scientists. Its product portfolio includes the neutrophil gelatinase-associated lipocalin (NGAL) test – a particle-enhanced turbidimetric assay designed to quantify NGAL levels, which complements existing clinical assessments and standard diagnostic procedures. Furthermore, it supplies monoclonal antibodies for scientific, pharmaceutical, and clinical research applications, along with enzyme-linked immunosorbent assay (ELISA) kits, automated in-vitro diagnostic assays, and a versatile rapid assay device platform for developing lateral flow assays.
- CEO
- Carsten Buhl
- IPO
- 2019
- Employees
- 46
- HQ
- Hellerup, CR, DK
Get TickerSpark's AI analysis on THOXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $73.77M
- P/E
- 80.08
- Fwd P/E
- 3.07
- PEG
- 0.36
- P/S
- 14.21
- P/B
- 6.40
- EV/EBITDA
- -9.64
- Div Yield
- 0.00%
- Gross Margin
- 76.14%
- Op Margin
- -130.76%
- Net Margin
- 23.31%
- ROE
- 14.20%
- ROIC
- -53.61%
Latest fiscal year · YoY change
- Revenue
- $40.20M+10.9%
- Gross Profit
- $27.95M+13.9%
- Op Income
- $-85,898,988
- Net Income
- $-81,930,998-20.1%
- EPS
- $-0.15+11.8%
- OCF Growth
- +8.0%
- FCF Growth
- +8.4%
- 52W High
- $0.31
- 52W Low
- $0.15
- 50D MA
- $0.15
- 200D MA
- $0.16
- Beta
- 1.38
- RSI (14)
- 0
- Avg Volume
- 19.33K
No earnings-call transcripts are available for THOXF yet.
- Free Float
- 92.7%
- Shares Outstanding
- 495.10M
- Float Shares
- 458.86M
Our THOXF coverage
Recent articles, reports, and earnings notes.
No research on THOXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate THOXF report →Grant of Warrants
globenewswire.com · Jun 15
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
globenewswire.com · Jun 9
BioPorto announces Interim Result for the First Quarter of 2026
globenewswire.com · May 21
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
globenewswire.com · May 12
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
globenewswire.com · Mar 31
Notice convening the Annual General Meeting in BioPorto A/S
globenewswire.com · Mar 26
BioPorto announces the Annual Report for 2025
globenewswire.com · Mar 26
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
globenewswire.com · Mar 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.